James Condulis
Stock Analyst at Stifel Nicolaus
(0.70)
# 4,183
Out of 5,090 analysts
66
Total ratings
33.3%
Success rate
-4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XFOR X4 Pharmaceuticals | Reiterated: Buy | $10 | $3.35 | +198.51% | 3 | Oct 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $136 → $156 | $85.00 | +83.53% | 9 | Oct 15, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $45 | $28.86 | +55.93% | 3 | Oct 1, 2026 | |
| BRVE Braveheart Bio | Reiterated: Buy | $45 | $21.51 | +109.21% | 4 | Oct 1, 2026 | |
| TECX Tectonic Therapeutic | Reiterated: Buy | $75 | $19.78 | +279.17% | 4 | Oct 1, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $18 | $6.83 | +163.54% | 1 | Sep 30, 2026 | |
| FULC Fulcrum Therapeutics | Rated: Hold | n/a | $3.71 | - | 6 | Sep 21, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $50 | $20.06 | +149.25% | 6 | Sep 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $104 | $59.90 | +73.62% | 3 | Aug 31, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Hold | $6 | $1.36 | +341.18% | 5 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $36 | $38.90 | -7.46% | 6 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $62.99 | +71.46% | 16 | Aug 7, 2026 |
X4 Pharmaceuticals
Oct 30, 2026
Reiterated: Buy
Price Target: $10
Current: $3.35
Upside: +198.51%
Mirum Pharmaceuticals
Oct 15, 2026
Reiterated: Buy
Price Target: $136 → $156
Current: $85.00
Upside: +83.53%
Amylyx Pharmaceuticals
Oct 1, 2026
Reiterated: Buy
Price Target: $45
Current: $28.86
Upside: +55.93%
Braveheart Bio
Oct 1, 2026
Reiterated: Buy
Price Target: $45
Current: $21.51
Upside: +109.21%
Tectonic Therapeutic
Oct 1, 2026
Reiterated: Buy
Price Target: $75
Current: $19.78
Upside: +279.17%
Achieve Life Sciences
Sep 30, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $6.83
Upside: +163.54%
Fulcrum Therapeutics
Sep 21, 2026
Rated: Hold
Price Target: n/a
Current: $3.71
Upside: -
NewAmsterdam Pharma Company
Sep 8, 2026
Reiterated: Buy
Price Target: $50
Current: $20.06
Upside: +149.25%
Arrowhead Pharmaceuticals
Aug 31, 2026
Reiterated: Buy
Price Target: $104
Current: $59.90
Upside: +73.62%
Aardvark Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: $6
Current: $1.36
Upside: +341.18%
Aug 11, 2026
Reiterated: Hold
Price Target: $36
Current: $38.90
Upside: -7.46%
Aug 7, 2026
Reiterated: Buy
Price Target: $108
Current: $62.99
Upside: +71.46%